United Therapeutics Launches $2B Buyback, Kicks Off $1.5B ASR Program
Event summary
- United Therapeutics authorized a $2B stock repurchase program over the next year.
- The company entered into a $1.5B accelerated share repurchase (ASR) agreement with Citibank.
- The remaining $500M will be available for additional repurchases at the company's discretion.
- The ASR includes a $750M uncollared agreement and a $750M collared agreement.
- Initial share deliveries are expected around March 11, 2026.
The big picture
United Therapeutics' aggressive $2B buyback plan underscores its confidence in sustained growth and cash flow, despite a perceived valuation disconnect. The move aligns with broader trends in the biotech sector, where companies with strong balance sheets are increasingly returning capital to shareholders. The scale of the repurchase—nearly 10% of its current market cap—positions United Therapeutics as a notable player in shareholder returns, potentially influencing peer strategies in capital allocation.
What we're watching
- Capital Allocation
- How United Therapeutics balances its $2B repurchase program with long-term growth objectives and R&D investments.
- Market Valuation
- Whether the company's confidence in its valuation disconnect will be validated by market performance.
- Execution Risk
- The pace at which the ASR program is completed and the impact of market volatility on the final share count.
Related topics